2nd Congress Unmet Needs & Sharing Risks


26 Oct 2007

Living Tomorrow in Vilvoorde

From 2005 until 2009, CROSSTALKS ran a bottom-up and interdisciplinary project “The Future of Medication in a Patient-centered Health Care”, a series of conferences and workshops to develop constructive dialogues between all the partners in the health care sector.

Crucial in this project was the collaborative partnership and sharing of knowledge between academics, industry, physicians, pharmacists, patients, sick funds and insurances, health and social care organizations and policymakers.


08:30 Registration & coffee

09:00 Brief welcome & introduction by Alain Dupont - Vice Dean Research, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel

Program Chairs:

Marc BOGAERT (former Dean of the Faculty of Pharmacy and Medicine, UGent)
Guy MANNAERTS (honorary president UZ KULeuven, Prof. Dept Pharmacology)

09:20 First lecture – Paradigm shift in rewarding innovation

What is in the pharma-industry’s pipeline? Can society pay for this? What is not being developed because of too high risks? (pharmaceuticals + medical devices) by Paul STOFFELS - Company Group Chairman Johnson & Johnson Pharmaceutical Research & Development/Chairman of Tibotec

10:10 Second lecture – Mechanisms for making long term choices

How are choices made within a restricted budget? Is there a medical/societal agreement? What is the framework, what are the mechanisms for rational decisions? (pharmaceuticals + medical devices) by Mercia Page - Clinical Practice Centre Director of the National Institute of Health & Clinical Excellence (NICE)

11:00 Coffee break

11:20 Third lecture – Co-payment and future socio-fiscal models

Looking ten to twenty years ahead: what could the next para-fiscal or socio-fiscal model be? What about co-payment and how does that manifests itself in a private-public co-operation context? Can we envision a model for research in which focus on specific issues, diseases, pharmaceuticals or medical devices is defined by government/society? by Orvill ADAMS - Director of Orvill Adams & Associates

12:10 Open discussion with panel

12:40 Apero + lunch

14:00 Fourth lecture – Corporate governance of all stakeholders in health care

Corporate governance is about a much larger group than the shareholders of the pharma industry. We’re talking here about the governance of all the stakeholders: doctors, pharmacists, hospitals, mutualities, policymakers by Guy PEETERS - General Secretary of the National Association of Socialist Mutualities

14:50 Fifth lecture – Pharma innovation and social justice

Of the so-called innovative pharmaceuticals, only one half has a real added value. What are the instruments, methods and regulations needed to establish a better balance between unmet needs and over-met needs? “Harnessing the Power of Pharmaceutical Innovation - A New Approach to Pharmaceutical Innovation” by Doris SCHROEDER - Head of Centre and Professor of Moral Philosophy, Centre for Professional Ethics, University of Central Lancashire

15:40 Final discussion

16:15 Closing remarks

16:30 Cocktail reception & networking

Artistic intervention in collaboration with Pharmacopeia and the Wellcome Trust (UK)

Bios / Slides


The congress “Unmet Needs & Shared Risks” took place on Friday October 26 in Living Tomorrow in Vilvoorde and lead CROSSTALKS halfway through the 3 year project “The Future of Medication”. By means of a series of congresses and workshops CROSSTALKS wants to develop an open and constructive trust relation between all stakeholders in health care.

Or as one of the congress chairs, Guy Mannaerts (honorary president UZ KULeuven), concluded the meeting: “I have understood today that it will be easier to come to a constructive treaty between the different players and in particularly between the pharmaceutical industry and the sickness funds than for our policy leaders to form a new government…”

As neutral and interdisciplinary discussion platform, CROSSTALKS offers
a unique and open context to approach complex themes from multiple perspectives.

Exactly from these open dialogues common challenges and interests emerge. The remarkable constructive propositions of the various speakers all accentuate the same goal: building bridges between the different stakeholders at national and international level and provide a better and more accessible health care for everybody.

Paul Stoffels (Company Group Chairman Johnson & Johnson Pharmaceutical Research) sketched in a crystal clear way how the pharmaceutical industry is supposed to deliver innovation in a context colored by stricter rules and regulations. The tension between the rising investment risks and the declining award system becomes sharper and if that tension does not decrease, the declining award system will cause a decrease in innovation and finally in an increasing health care burden.


This project could be realized due to unconditional grants by

Astra Zeneca Foundation
Janssen Pharmaceutica